EASD 2023 - Andrew Frankel and Daniel van Raalte debating SGLT-2 inhibition for diabetes and CKD @EASDiabetes

EASD 2023 - Andrew Frankel and Daniel van Raalte debating SGLT-2 inhibition for diabetes and CKD @EASDiabetes

Uploaded October 2023 | Updated September 2026, 3 days ago

Andrew Frankel and Daniel van Raalte had an intense debate on EASD TV whether all people with
#diabetes and chronic kidney disease should be on SGLT-2 inhibition by default.
#EASD2023 #kidneydisease #ckd

EASD 2023 - Andrew Frankel and Daniel van Raalte debating SGLT-2 inhibition for diabetes and CKD

Best of EASD 2025 by the EASD Early Career Academy - featuring Dr. Eugenia Martin-Vazquez

EASD 2023 - What have cohort studies taught us about the natural history of type 2 diabetes?

EASD 2024: The Sky is NOT the Limit! Ensuring Safe Travel for People Living with Diabetes

EASD 2025: Recurrent Severe Hypoglycaemic Events: What to do?

Best of EASD 2025 by the EASD Early Career Academy – featuring Romane Lartigue

EASD Live 2023

2nd EASD Early Career Academy Webinar: Perfecting your grant application

Main pillars of kidney protection in diabetes, and how they may apply in type 1 diabetes

EASD 2023 - Maria Redondo and Emily Sims about type 1 diabetes heterogeneity and screening

4th EASD Early Career Academy Journal Club - 6 Apr 2023

EASD Presidency Transition: A Conversation with Chantal Mathieu and Francesco Giorgino

European Association for the Study of Diabetes |

EASD 2023 - Andrew Frankel and Daniel van Raalte debating SGLT-2 inhibition for diabetes and CKD